688105 Stock Overview
Offers technology solutions for life science, biomedicine, and in vitro diagnostics. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Nanjing Vazyme Biotech Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥22.17 |
| 52 Week High | CN¥32.40 |
| 52 Week Low | CN¥16.85 |
| Beta | 0.98 |
| 1 Month Change | -8.39% |
| 3 Month Change | -8.84% |
| 1 Year Change | -29.62% |
| 3 Year Change | -78.40% |
| 5 Year Change | n/a |
| Change since IPO | -74.02% |
Recent News & Updates
Nanjing Vazyme Biotech's (SHSE:688105) Shareholders May Want To Dig Deeper Than Statutory Profit
Nov 07
Nanjing Vazyme Biotech Co., Ltd's (SHSE:688105) 45% Price Boost Is Out Of Tune With Revenues
Oct 08Recent updates
Nanjing Vazyme Biotech's (SHSE:688105) Shareholders May Want To Dig Deeper Than Statutory Profit
Nov 07Nanjing Vazyme Biotech Co., Ltd's (SHSE:688105) 45% Price Boost Is Out Of Tune With Revenues
Oct 08Is Nanjing Vazyme BiotechLtd (SHSE:688105) Using Debt In A Risky Way?
Jun 26Nanjing Vazyme Biotech Co.,Ltd's (SHSE:688105) Shares Climb 31% But Its Business Is Yet to Catch Up
Mar 06Shareholder Returns
| 688105 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -4.3% | -0.8% | 1.0% |
| 1Y | -29.6% | -22.3% | 8.2% |
Return vs Industry: 688105 underperformed the CN Biotechs industry which returned -22.3% over the past year.
Return vs Market: 688105 underperformed the CN Market which returned 8.2% over the past year.
Price Volatility
| 688105 volatility | |
|---|---|
| 688105 Average Weekly Movement | 8.7% |
| Biotechs Industry Average Movement | 7.9% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in CN Market | 12.2% |
| 10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 688105 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688105's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 2,637 | Lin Cao | www.vazyme.com |
Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers reagents for molecular biology research, such as nucleic acid extraction, PCR, cloning/mutagenesis, nucleic acid electrophoresis, reverse transcription, real-time PCR (qPCR), genome editing, and cell biology/protein research; reagents for NGS library preparation, including automated liquid handling workstation, DNA sequencing, RNA sequencing, single cell-seq series, epigenetics series, beads series, quantification series, and capture series; reagents for molecular diagnosis comprising isothermal amplification reagents, PCR, reverse transcription, real-time PCR, one-step series, and animal detection; and reagents for bio-medicine, such as vaccine effectiveness evaluations and vaccine manufacture. Nanjing Vazyme Biotech Co., Ltd was founded in 2012 and is based in Nanjing, China.
Nanjing Vazyme Biotech Co., Ltd Fundamentals Summary
| 688105 fundamental statistics | |
|---|---|
| Market cap | CN¥8.96b |
| Earnings (TTM) | CN¥23.59m |
| Revenue (TTM) | CN¥1.40b |
371.5x
P/E Ratio6.2x
P/S RatioIs 688105 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688105 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.40b |
| Cost of Revenue | CN¥553.22m |
| Gross Profit | CN¥849.39m |
| Other Expenses | CN¥825.80m |
| Earnings | CN¥23.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 10, 2025
| Earnings per share (EPS) | 0.06 |
| Gross Margin | 60.56% |
| Net Profit Margin | 1.68% |
| Debt/Equity Ratio | 11.6% |
How did 688105 perform over the long term?
See historical performance and comparisonDividends
0.3%
Current Dividend Yield201%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 09:48 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nanjing Vazyme Biotech Co., Ltd is covered by 9 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Pei Cheng | China Galaxy Securities Co., Ltd. |
| Yuan Gao | China International Capital Corporation Limited |
| Jin Zhang | China International Capital Corporation Limited |